Table 2.
Univariate analyses of indicators for pathological complete response to preoperative chemoradiotherapy in locally advanced rectal cancer.
| Variable | pCR n=126 (% of total) | Non-pCR n=418 (% of total) | Odds ratio (95% CI) | p-value |
|---|---|---|---|---|
| Gender | 0.895 | |||
| Male | 83 (23.0) | 278 (77.0) | Reference | |
| Female | 43 (23.5) | 140 (76.5) | 1.029 (0.676-1.567) | |
| Age (years) | 0.546 | |||
| ≤60 | 83 (24.0) | 263 (76.0) | Reference | |
| >60 | 43 (21.7) | 155 (78.3) | 0.879 (0.579-1.336) | |
| Post-CRT BMI (kg/m2)a | 0.143 | |||
| ≤25 | 103 (35.4) | 188 (64.6) | Reference | |
| >25 | 23 (22.1) | 81 (77.9) | 0.655 (0.372-1.53) | |
| Chemotherapy regimen | 0.129 | |||
| Capecitabine | 2 (0.09) | 20 (0.91) | Reference | |
| XELOX and FOLFOX | 124 (23.8) | 398 (76.2) | 3.116 (0.718-13.516) | |
| Radiation pattern | 0.198 | |||
| 3D-CRT | 47 (20.4) | 183 (79.6) | Reference | |
| IMRT | 79 (25.2) | 235 (74.8) | 1.309 (0.869-1.971) | |
| Dose of radiotherapy (Gy) | 0.044 | |||
| <50 | 51 (19.4) | 212 (80.6) | Reference | |
| ≥50 | 75 (26.7) | 206 (73.3) | 1.513 (1.010-2.267) | |
| ycT stage | 0.006 | |||
| 3-4 | 108 (21.8) | 387 (78.2) | Reference | |
| 0-2 | 18 (36.7) | 31 (63.3) | 2.414 (1.281-4.547) | |
| ycN stage | 0.002 | |||
| 1-2 | 37 (16.7) | 184 (83.3) | Reference | |
| 0 | 89 (27.6) | 234 (72.4) | 1.952 (1.267-3.009) | |
| Post-CRT DAV (cm) | 0.044 | |||
| >5 | 73 (23.5) | 283 (76.5) | Reference | |
| ≤5 | 53 (28.2) | 135 (71.8) | 1.522 (1.011-2.291) | |
| Tumor differentiation | 0.510 | |||
| Well and moderate | 100 (23.8) | 320 (76.2) | Reference | |
| Poor | 26 (21.0) | 98 (79.0) | 0.849 (0.522-1.382) | |
| Interval from completion of CRT to surgery (weeks) | 0.020 | |||
| ≤7 | 43 (18.3) | 192 (81.7) | Reference | |
| >7 | 83 (26.9) | 226 (73.1) | 1.640 (1.082-2.485) | |
| Post-CRT CEA (ng/ml)b | 0.037 | |||
| >2 | 64 (20.3) | 251 (79.7) | Reference | |
| ≤2 | 53 (28.5) | 133 (71.5) | 1.563 (1.027-2.379) |
CI: confidence interval, BMI: body mass index, DAV: distance of inferior tumor margin from the anal verge, CEA: carcinoembryonic antigen, pCR: pathologic complete response, ycT stage: clinical tumor stage after chemoradiotherapy, ycN stage: clinical node stage after chemoradiotherapy, 3D-CRT: three-dimensional conformal radiation therapy, IMRT: intensity-modulated radiation therapy, CRT: chemoradiotherapy
a
There were only 395 patients with complete data for post-CRT BMI.
b
There were only 501 patients with complete data for post-CRT CEA.